Paper Details

  1. Home
  2. Paper Details

Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler.

Author: BarrazaC H, BouletL P, BousquetJ, D'UrzoA, HarnestU, HebertJ, LundbäckB, LutskyB N, Martinez MoralesG, NieminenM M, NolopK B, Suárez-ChacónR, VisserS

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study compared the effectiveness and tolerability of mometasone furoate (MF) administered by dry powder inhaler (DPI) and budesonide (BUD) Turbuhaler in patients with moderate persistent asthma. MF DPI 200 and 400 microg b.i.d showed significantly better improvement in lung function compared to BUD Turbuhaler 400 microg b.i.d. MF DPI was well tolerated and the incidence of oral candidiasis was low.
Paper Details　
Original Abstract of the Article :
Mometasone furoate (MF) administered by dry powder inhaler (DPI) was composed with budesonide (BUD) Turbuhaler in the treatment of moderate persistent asthma. The patients were randomized to one of four treatment groups: MF DPI (100, 200, 400 microg b.i.d) or BUD Turbuhaler. 400 microg b.i.d in a 12...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1183/09031936.00.16580800

データ提供：米国国立医学図書館（NLM）

Mometasone Furoate vs. Budesonide for Moderate Persistent Asthma

Asthma, a condition that makes breathing difficult, can be a real desert windstorm for those who suffer from it. This research explores the effectiveness of two inhaled corticosteroids, mometasone furoate (MF) and budesonide (BUD), in managing moderate persistent asthma. Using a well-designed study involving a randomized controlled trial, a process akin to exploring different paths across the desert to find the most suitable route, researchers compared the efficacy and safety of these two medications. Their findings, like a refreshing spring amidst the desert, indicate that mometasone furoate delivered via a dry powder inhaler (DPI) showed statistically significant superiority compared to budesonide Turbuhaler for several efficacy variables, including improved lung function. This is a significant discovery as it offers a new and promising therapeutic option for asthma management.

Mometasone Furoate: A Superior Choice for Asthma

This study clearly demonstrates that mometasone furoate delivered via a dry powder inhaler (DPI) is a superior choice for patients with moderate persistent asthma. The statistical significance of the results, like a beacon in the desert, illuminates the potential of mometasone furoate as a therapeutic option. This study provides valuable insights into the management of asthma, offering patients and doctors more choices to navigate the desert of this complex condition.

A Breath of Fresh Air for Asthma Sufferers

This research offers a breath of fresh air for asthma sufferers. The discovery of a superior treatment option, mometasone furoate DPI, brings a much-needed sense of hope and control over this challenging condition. This is like finding a hidden oasis in the heart of the desert, a refuge from the harshness of the condition. The researchers have paved a smoother path for those struggling with asthma, offering a chance for a better quality of life.

Dr.Camel's Conclusion

This research is a true beacon in the desert of asthma management. It provides solid evidence for the effectiveness of mometasone furoate DPI, offering a superior treatment option for those struggling with this condition. This research is a true testament to the power of scientific inquiry, a commitment to finding solutions for those who need them most. It's a reminder that the desert of medical challenges can be overcome with perseverance and a willingness to explore new paths.

Date :
  1. Date Completed 2001-03-22
  2. Date Revised 2019-08-22
Further Info :

Pubmed ID

11153576

DOI: Digital Object Identifier

10.1183/09031936.00.16580800

Related Literature

Article Analysis
・Effects of mometasone oral inhalation
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.